Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options
{{output}}
The Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and the Irbesartan Diabetic Nephropathy Trial (IDNT) are two recently reported trials with hard end points, conducted in patients in advanced stages of diabetic nep... ...
